(Q50455744)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24864047%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

title

Transient MEK inhibitor-associated retinopathy in metastatic melanoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24864047%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24864047%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

author name string

U Urner-Bloch

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24864047%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

P Stieger

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24864047%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

N Galliker

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24864047%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

N Winterton

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24864047%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

A Zubel

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24864047%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

L Moutouh-de Parseval

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24864047%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

R Dummer

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24864047%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

S M Goldinger

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24864047%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

publication date

26 May 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24864047%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24864047%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24864047%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24864047%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

page(s)

1437-1441

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24864047%20AND%20SRC:MED&resulttype=core&format=json

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

19 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU169

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU169

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU169

From basic research to clinical development of MEK1/2 inhibitors for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU169

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU169

The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU169

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU169

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU169

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU169

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU169

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU169

Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU169

Combination molecularly targeted drug therapy in metastatic melanoma: progress to date.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU169

RASopathic skin eruptions during vemurafenib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU169

Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU169

Ocular toxicity of targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU169

PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU169

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU169

Central serous chorioretinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU169

Choroidal capillary and venous congestion in central serous chorioretinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU169

Metastatic melanoma in the eye and orbit

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU169

Neoplastic masquerade syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU169

Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU169

The mystery of angiographically silent macular oedema due to taxanes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU169

Etiology and treatment of macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU169

Nonsteroidal anti-inflammatory drugs in ophthalmology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU169

The role of carbonic anhydrase inhibitors in the management of macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU169

Acetazolamide for central serous retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU169

Topical dorzolamide therapy for taxane-related macular oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU169

Treatment of cystic macular lesions in hereditary retinal dystrophies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU169

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDU169

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24864047%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

1 reference